Challenges and pitfalls of combining targeted agents in phase I studies

被引：43

作者：

Cannistra, Stephen A. ^{[1
]}

机构：

[1] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 22期

关键词：

D O I：

10.1200/JCO.2008.17.2676

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3665 / 3667

页数：3

共 18 条

[1] Azad NS, 2007, J CLIN ONCOL, V25
[2] Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity
Azad, Nilofer S.
Posadas, Edwin M.
Kwitkowski, Virginia E.
Steinberg, Seth M.
Jain, Lokesh
Annunziata, Christina M.
Minasian, Lori
Sarosy, Gisele
Kotz, Herbert L.
Premkumar, Ahalya
Cao, Liang
McNally, Deborah
Chow, Catherine
Chen, Helen X.
Wright, John J.
Kohn, Elise C.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) : 3709 - 3714
[3] Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic oncology group study
Burger, Robert A.
Sill, Michael W.
Monk, Bradley J.
Greer, Benjamin E.
Sorosky, Joel I.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) : 5165 - 5171
[4] Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
Cannistra, Stephen A.
Matulonis, Ursula A.
Penson, Richard T.
Hambleton, Julie
Dupont, Jakob
Mackey, Howard
Douglas, Jeffrey
Burger, Robert A.
Armstrong, Deborah
Wenham, Robert
McGuire, William
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) : 5180 - 5186
[5] Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models
Chang, Yong S.
Adnane, Jalila
Trail, Pamela A.
Levy, Joan
Henderson, Arris
Xue, Dahai
Bortolon, Elizabeth
Ichetovkin, Marina
Chen, Charles
McNabola, Angela
Wilkie, Dean
Carter, Christopher A.
Taylor, Ian C. A.
Lynch, Mark
Wilhelm, Scott
[J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 59 (05) : 561 - 574
[6] Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors
Clark, JW
Eder, JP
Ryan, D
Lathia, C
Lenz, HJ
[J]. CLINICAL CANCER RESEARCH, 2005, 11 (15) : 5472 - 5480
[7] Sorafenib in advanced clear-cell renal-cell carcinoma
Escudier, Bernard
Eisen, Tim
Stadler, Walter M.
Szczylik, Cezary
Oudard, Stephane
Siebels, Michael
Negrier, Sylvie
Chevreau, Christine
Solska, Ewa
Desai, Apurva A.
Rolland, Frederic
Demkow, Tomasz
Hutson, Thomas E.
Gore, Martin
Freeman, Scott
Schwartz, Brian
Shan, Minghua
Simantov, Ronit
Bukowski, Ronald M.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) : 125 - 134
[8] Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22
Fisher, B
Anderson, S
Wickerham, DL
DeCillis, A
Dimitrov, N
Mamounas, E
Wolmark, N
Pugh, R
Atkins, JN
Meyers, FJ
Abramson, N
Wolter, J
Bornstein, RS
Levy, L
Romond, EH
Caggiano, V
Grimaldi, M
Jochimsen, P
Deckers, P
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) : 1858 - 1869
[9] Giantonio BJ, 2006, J CLIN ONCOL, V24, p155S
[10] Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
Giantonio, Bruce J.
Catalano, Paul J.
Meropol, Neal J.
O'Dwyer, Peter J.
Mitchell, Edith P.
Alberts, Steven R.
Schwartz, Michael A.
Benson, Al B., III
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (12) : 1539 - 1544

← 1 2 →